Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus EP/EC in advanced extrapulmonary neuroendocrine carcinoma
NCT05076786Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT05076786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076786.